U.S. Senate Finance Committee Chair Ron Wyden (D-OR) issued a release on 4 April 2022 regarding his continued investigation into the tax practices of multinational pharmaceutical companies to abuse tax havens and avoid paying U.S. tax. --- Senator Wyden Continues Investigation into Big Pharma Tax Practices Following letters to AbbVie and Bristol Myers Squibb, Wyden requests information from Merck, which reports just 14 percent of pretax income in the United States despite U.S. market being home to 46 percent of global sales Washington, D.C. – Senate Finance Committee Chair Ron Wyden, D-Ore., today continued his investigation into Big Pharma's tax...